Improving cancer treatment with cyclotron produced radionuclides. [Multiple Drug Resistance (MDR)]

Technical Report · Mon Oct 15 04:00:00 EDT 1990

DOI:https://doi.org/10.2172/6253141· OSTI ID:6253141

Larson, S M; Finn, R D

The overall objective of this work was to promote nuclear medicine applications in oncology. This is being done by improving the scientific basis of diagnosis, treatment and treatment follow-up with cyclotron-produced tracers. For diagnostic use, positron-emitting isotopes such as Ga-66 and I-124 are being used. Initial studies on the characterization of He-4 particle energies required for Ga-66 production have been completed. Parameters for I-124 radiolabelling of monoclonal antibodies have been determined; the labelled antibodies have been used in animal studies using positron emission tomography (PET) to quantify antibody concentration within tumors in vivo. Imaging physics studies have demonstrated that I-124 can be quantitatively imaged by PET, even in the presence of 100-told greater concentrations of I-131. Measurement of concentrations of label in vivo has been accomplished in nuclei mice bearing neuroblastoma tumors and nude rats bearing human ovarian cancer cells. These studies have major implications for both the quantification of dosimetry and quantification kinetic assessment of anti-tumor antibody localization in vivo. For treatment of tumors, F-18 has been incorporated in 2-fluoro-2-deoxy glucose and 5-fluoro uridine, and O-15 labelled water has been produced. Reagents incorporating C-11 and N-13 are under development. In a related area, C-14 labelled colchicine is being studied as a means of assaying cells for multiple drug resistance (MDR). Cells expressing MDR are shown to retain significantly less C-14 colchiene. This suggest that colchiene retention may be of useful probe in modelling and studying MDR development in human tumors. The precursor required for producing C-11 colchicine has also been synthesized. 11 refs. (MHB)

• Research Organization: Sloan-Kettering Inst. for Cancer Research, New York, NY (USA)
• Sponsoring Organization: DOE/ER
• DOE Contract Number: FG02-86ER60407
• OSTI ID: 6253141
• Report Number(s): DOE/ER/60407-4; ON: DE91007335
• Country of Publication: United States
• Language: English

Related Subjects

550601* -- Medicine-- Unsealed Radionuclides in Diagnostics
550604 -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ACCELERATORS
ANIMAL CELLS
ANTIBODIES
COMPUTERIZED TOMOGRAPHY
CYCLIC ACCELERATORS
CYCLOTRONS
DIAGNOSTIC TECHNIQUES
DISEASES
DOCUMENT TYPES
DRUGS
EMISSION COMPUTED TOMOGRAPHY
IMMUNOLOGY
IMMUNOTHERAPY
ISOTOPE APPLICATIONS
LABELLED COMPOUNDS
LABELLING
MEDICINE
MONOCLONAL ANTIBODIES
NEOPLASMS
NUCLEAR MEDICINE
POSITRON COMPUTED TOMOGRAPHY
PROGRESS REPORT
RADIOASSAY
RADIOIMMUNODETECTION
RADIOIMMUNOLOGY
RADIOIMMUNOTHERAPY
RADIOLOGY
RADIOPHARMACEUTICALS
RADIOTHERAPY
THERAPY
TOMOGRAPHY
TRACER TECHNIQUES
TUMOR CELLS